Drug Trial Radar · NCT01020838
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
218
Actual
Start
Nov 2009
Primary completion
Sep 2011
Study completion Dec 2013
Sponsor
- Lead sponsor
- Lantheus Biosciences Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective histopathologic post mortem specimens as the standard of truth
Conditions
- Alzheimer Disease
Interventions
Florbetaben (BAY94-9172)Drug
Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and Specificity of the Majority Read of Visual Assessment of Tracer Uptake Compared to Histological Verification of the Presence or Absence of Cerebral Beta-amyloid in Postmortem SpecimensTime frame: 90-110 minutes post injection (PET image acquisition)
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Site not named
Sun City, Arizona
Site not named
Stanford, California
Site not named
Tampa, Florida
Site not named
Teaneck, New Jersey
Site not named
Philadelphia, Pennsylvania
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Heidelberg, Victoria, Australia
Site not named
Lille, France
Site not named
Strasbourg, France
Site not named
Jülich, North Rhine-Westphalia, Germany
Site not named
Leipzig, Saxony, Germany
Site not named
Toyohashi, Aichi-ken, Japan
Site not named
Toyohashi, Aichi-ken, Japan
Site not named
Toyohashi, Aichi-ken, Japan
Site not named
Isesaki, Gunma, Japan
Site not named
Hamamatsu, Shizuoka, Japan
Site not named
tabashi City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.